Abstract
Secondary central nervous system (CNS) progression in patients with non-Hodgkin lymphoma (NHL) is associated with a particularly poor prognosis. In this review, we summarize and critically evaluate the current literature to guide the practicing clinician in estimating CNS relapse risk in order to select individual patients who may benefit from CNS prophylaxis, covering histologic subtype, anatomic location, and molecular and clinical factors. We summarize the data regarding different prophylaxis strategies used and provide our recommendation regarding who should receive it, what they should receive, and when it should be administered. © 2015, Springer Science+Business Media New York.
| Original language | English |
|---|---|
| Journal | Current Oncology Reports |
| Volume | 17 |
| Issue number | 6 |
| Early online date | 28 Apr 2015 |
| DOIs | |
| Publication status | Published - 1 Jun 2015 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Central Nervous System Prophylaxis in Non-Hodgkin Lymphoma: Who, What, and When?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver